 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

This price move could indicate a change in the trend, and may be a sell signal for investors...

Merus (MRUS, $23.58) price exceeded its 50-day Moving Average on September 29, 2023

MRUS's total volume now sits at 1.3M. The +1.58% price change was insignificant, leaving IBM's price at $24.47...

The volume for Merus stock increased for one day, resulting in a record-breaking daily growth of 407% of the 65-Day Volume Moving Average

This price move could indicate a change in the trend, and may be a buy signal for investors...

Merus (MRUS, $24.09) price moved above its 50-day Moving Average on September 27, 2023

This is a signal that MRUS's price trend could be reversing, and it may be an opportunity to buy the stock or explore call options...

Merus (MRUS, $24.09) Stochastic Oscillator left the oversold zone on September 27, 2023

Merus (MRUS, $22.77) Stochastic Oscillator left the oversold zone on September 26, 2023

This is a Bearish indicator signaling MRUS's price could decline from here. Traders may explore shorting the stock or put options...

Merus (MRUS, $22.6) Moving Average Convergence Divergence (MACD) Histogram turned negative on September 25, 2023

This indicator may be signaling that MRUS's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...

Merus (MRUS, $22.6) entered Downtrend as Momentum indicator drops below 0 level on Sep 25, 2023

Pancreatic Cancer Research Gains Momentum Amidst Soaring Young-Onset Cases Pancreatic Cancer Research Gains Momentum Amidst Soaring Young-Onset Cases PR Newswire VANCOUVER, British Columbia, Sept...

Pancreatic Cancer Research Gains Momentum Amidst Soaring Young-Onset Cases

Merus (MRUS, $23.95) price exceeded its 50-day Moving Average on September 22, 2023

Needham  Company LLC reissued their buy rating on shares of Merus (NASDAQ:MRUS  Free Report) in a report published on Thursday, Benzinga reports. The firm currently has a $45.00 price...

Merus (NASDAQ:MRUS) Earns Buy Rating from Needham & Company LLC

Merus NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors. The company was founded by Ton Logtenberg and Hennie Hoogenboom on June 16, 2003 and is headquartered in Utrecht, the Netherlands.

Watchers	799
52-Wk Low	$12.03
52-Wk High	$27.70

Market Cap	$1.34B
Volume (M)	474,792.00
52-Wk High	$27.70
52-Wk Low	$12.03

Current Price	$23.58
Prev Close	$24.47
Open	$24.51
Dividend Yield	0.00%
50-Day Moving Average	$23.67
Beta	0.87
Avg. Volume	254,640.78
PE Ratio	-6.16

52-Week High	$27.70
52-Week Low	$12.03
Market Capitalization	$1.34B
EPS	-$3.83
Price to Book	4.57
Revenue Per Employee	N/A
Enterprise Value/EBITDA	-5.98

MRUS Merus N.V

About

Feed

News

Sentiment

Earnings

Fundamentals